NCT01503047已完成4 期
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tonalin(R)Intake in Overweight People
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2008年3月最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 2
- 主要终点
- body composition(DXA)
研究概览
简要总结
The aim of the study was to examine the effects and safety of 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) on weight control and body composition in healthy overweight individuals who maintained their normal dietary and exercise patterns.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 30 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •aged 30-55 years
- •grade II overweight (BMI≥27 but <30 kg/m2)
- •not to be adhered to any calorie restriction diet
- •not to be taking any weight control medication or have lost more than 5 kg in the three months prior to the study
排除标准
- •suffering of serious concomitant disease such as diabetes mellitus type II, metabolic syndrome (according to the criteria of the Adult Treatment Panel III), cancer, kidney disease, HIV, tuberculosis, cardiovascular disease, chronic obstructive pulmonary disease, eating disorders.
- •having undergone bariatric surgery and/or intestinal resection
- •breastfeeding and pregnancy.
- •not to give their signed, informed consent to be included in the study.
结局指标
主要结局
body composition(DXA)
时间窗: 0, 3, 6 months
次要结局
- anthropometric parameters(0,1, 2, 3, 4, 5 and 6 month)
- Biochemical parameters(0, 3 and 6 month)
- HOMA-Index(0, 3, 6 month)
研究者
Ignacio Galicia
Director
Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic GastroparesisGastroparesisDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01452815Tranzyme, Inc.201
已完成
3 期
Study Comparing Etanercept 50 mg Once Weekly to 25 mg Twice Weekly in Patients With Ankylosing SpondylitisAnkylosing SpondylitisNCT00418548Wyeth is now a wholly owned subsidiary of Pfizer350
已完成
1 期
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer DiseaseNCT03522129Cognition Therapeutics3
已完成
2 期
12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking CessationSmoking CessationNCT00139750Pfizer600
已完成
3 期
A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPDCOPDNCT00215436Dey345